Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carc...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Olsen, Ingrid H., Sørensen, Jens B., Federspiel, Birgitte, Kjaer, Andreas, Hansen, Carsten P., Knigge, Ulrich, Langer, Seppo W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: The Scientific World Journal 2012
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432352/
https://ncbi.nlm.nih.gov/pubmed/22973169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1100/2012/170496
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items